Bayesian Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bayesian Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-952	Closed	-$678K	–	906
2024 Q4	$678K	Buy	+952	New	+$799K	0.08%	309
2021 Q2	–	Sell	-764	Closed	-$361K	–	609
2021 Q1	$361K	Sell	764 -167	-18%	-$81.3K	0.08%	309
2020 Q4	$450K	Buy	+931	New	+$503K	0.12%	229
2020 Q1	–	Sell	-7,830	Closed	-$2.94M	–	938
2019 Q4	$2.94M	Buy	+7,830	New	+$2.63M	0.5%	34
2018 Q1	–	Sell	-4,200	Closed	-$1.58M	–	777
2017 Q4	$1.58M	Buy	+4,200	New	+$1.7M	0.32%	78

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bayesian Capital Management's REGN Position: Q1 2025 in Review

Bayesian Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 952 shares — an estimated $678K sold.

Bayesian Capital Management first reported a position in REGN in Q4 2017 and held it in 5 quarters. The position peaked at $2.94M in Q4 2019. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Bayesian Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 952 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $678K.
Bayesian Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Bayesian Capital Management's Regeneron Pharmaceuticals position peaked at $2.94M in Q4 2019.
1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.